Peptide Biomarker Discovery at its best!

Biomarkers play important roles in preclinical and clinical drug research and development. They are used for drug profiling, prediction and early detection of desired drug actions and adverse drug reactions. Biomarkers are in the emergence of targeted molecular medicine with theranostic product opportunities.

Digilab Peptidomics’s core expertise is the discovery of peptide biomarkers. Our solid expertise in peptide chemistry, mass spectrometry and bioinformatics as well as in medicine, biology and protease biochemistry allows us to offer an extensive range of services – from study design and optimised sampling procedures to comprehensive high resolution peptide profiling, peptide sequence identification and data interpretation – providing you with valuable solutions, not just analytical data.

With our Clinical Peptidomics® we support clinical studies, identifying of biomarkers that have the ability to differentially diagnose a disease, predict a patient’s response to therapy, monitor the effect of a therapy or assess the risk of side effects.

Digilab Peptidomic’s analytical services are available within the framework of a research collaboration or in a fee-for-service arrangement.

Digilab in its own discovery efforts has discovered peptide biomarkers that are available for in-licensing in the following Disease Areas:

• Pre/Diabetes & Metabolic Syndrome
• Alzheimer’s Disease
• Breast Cancer

For more information please contact us.